Protagonist Therapeutics has been granted a patent for peptide inhibitors of the interleukin-23 receptor, which can be used to treat inflammatory bowel disease and other disorders. The pharmaceutical composition includes the peptide inhibitor and a carrier. GlobalData’s report on Protagonist Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Protagonist Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Protagonist Therapeutics, Cyclosporin derivatives was a key innovation area identified from patents. Protagonist Therapeutics's grant share as of February 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Peptide inhibitors for treating inflammatory bowel disease

Source: United States Patent and Trademark Office (USPTO). Credit: Protagonist Therapeutics Inc

A recently granted patent (Publication Number: US11884748B2) discloses a pharmaceutical composition comprising a peptide inhibitor of an interleukin-23 receptor, along with a pharmaceutically acceptable carrier, excipient, or diluent. The peptide inhibitor of the interleukin-23 receptor is specifically identified as Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[Aib]-[Lys(Ac)]-NA-NH2 (SEQ ID NO:880) or a pharmaceutically acceptable salt thereof. This composition aims to target and inhibit the interleukin-23 receptor, potentially offering therapeutic benefits in relevant medical conditions.

The patent further details various specific peptide inhibitors of the interleukin-23 receptor that can be included in the pharmaceutical composition. These inhibitors are designed to interact with the interleukin-23 receptor, thereby modulating its activity. By utilizing these specific peptide inhibitors in the disclosed composition, the patent aims to provide a novel approach for targeting the interleukin-23 receptor and potentially treating associated diseases or conditions. The inclusion of these precise peptide inhibitors highlights the specificity and targeted nature of the pharmaceutical composition, potentially offering a more tailored and effective treatment option for relevant medical conditions.

To know more about GlobalData’s detailed insights on Protagonist Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies